Selumetinib Withdrawn Phase 2 Trials for Advanced Lung Cancer / Malignant Neoplasm of Respiratory and Intrathoracic Organ Carcinoma / Recurrent Nonsmall Cell Lung Cancer Treatment

IndicationsStatusPurposePhase
WithdrawnTreatment2
clinicaltrials.gov IdentifierTitleDrugs
NCT03004105MEDI4736 With Selumetinib for KRAS Mutant Non-Small Cell Lung Cancer (NSCLC)